The 10 Best ETFs of February 2018

The 10 Best ETFs of February 2018

Explore stocks on Coinbase

February was a crazy month for investors; consequently, the landscape of best-performing exchange-traded funds expanded from primarily biotech and emerging-market ETFs in January to several other spaces for this edition of the best ETFs of the month.

In February, the fortitude of those with generally bullish outlooks was tested as the Dow Jones Industrial Average made historic 1,000-plus point drops twice in less than two weeks. Meanwhile, the S&P 500 is down more than 4% on the month.

The turmoil is mostly attributed to anticipation of a rise in interest rates based on expectations of inflation in the months ahead. But outside of these struggles, some ETFs still managed to maintain impressive performances, while others managed to step up and replace old champions.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

In no particular order, here are the best ETFs of February, excluding leveraged funds and exchange-traded notes.

Best ETFs of February: ProShares Long Online/Short Stores ETF (CLIX)

Best ETFs of February: ProShares Long Online/Short Stores ETF (CLIX)
Best ETFs of February: ProShares Long Online/Short Stores ETF (CLIX)

Source: Shutterstock

Expense Ratio: 0.65%
YTD Performance: 18% vs 2% for the S&P 500

Among the best ETFs of February were several retail-based ETFs. Notably, the ProShares Long Online/Short Stores ETF (NYSEARCA:CLIX) manged to stand out from the crowd, as it has significantly outperformed the S&P 500 in 2018 so far.

This recently founded ProShares ETF is distinct in that it has a multifaceted strategy that aims to take full advantage of the death of traditional retail while also focusing on the rise of internet retailers. The CLIX achieves this by shorting traditional retail stocks and simultaneously holding online retailers with significant growth. As such, its holdings are constantly varying.

In simplest terms, the long/short approach of this ETF means investors “benefit from both outperforming online and underperforming physical retailers.”

Best ETFs of February: Loncar Cancer Immunotherapy ETF (CNCR)

Best ETFs of February: Loncar Cancer Immunotherapy ETF (CNCR)
Best ETFs of February: Loncar Cancer Immunotherapy ETF (CNCR)

Source: Shutterstock

Expense Ratio: 0.79%
YTD Performance: 23%

Last month, the Loncar Cancer Immunotherapy ETF (NASDAQ:CNCR) made it on the list of best-performing ETFs and it continued its success in February with an impressive 20% advantage over the S&P.

For those who are unfamiliar with CNCR, it’s a biotech ETF that emphasizes companies that are involved with cancer research and treatment.

More specifically, CNCR’s holdings must have cancer immunotherapy drugs that are approved by the FDA or EMA, are in human testing stages, are about to enter human testing stages and/or are involved with other companies that focus on immunotherapy. This includes companies like Aduro BioTech Inc (NASDAQ:ADRO) and AstraZeneca plc (ADR) (NYSE:AZN), which are among its top 10 holdings.